First-time use of newer oral contraceptives and the risk of venous thromboembolism
- 1 September 1997
- journal article
- research article
- Published by Elsevier BV in Contraception
- Vol. 56 (3), 141-146
- https://doi.org/10.1016/s0010-7824(97)00119-4
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- End of the line for “third-generation-pill” controversy?The Lancet, 1997
- Population-based study of risk of venous thromboembolism associated with various oral contraceptivesThe Lancet, 1997
- Oral contraceptives and thrombotic diseases: Impact of new epidemiological studiesContraception, 1996
- The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational researchContraception, 1996
- Comments on Desogestrel and Gestoden (3rd Generation Progestogens) and the Incidence of ThromboembolismHormone and Metabolic Research, 1996
- Are third-generation oral contraceptives safe?Human Reproduction, 1996
- Oral contraceptives and thrombotic diseases: Impact of new epidemiological studiesContraception, 1996
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995